Reviva Pharmaceuticals (RVPH) EBITDA (2018 - 2026)
Reviva Pharmaceuticals (RVPH) EBITDA from May 31, 2018 to Mar 31, 2026. The TTM Reviva Pharmaceuticals (RVPH) EBITDA is -$17M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Reviva Pharmaceuticals (RVPH) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -41.47% |
| 3 Years TTM | -15.83% |
| 5 Years TTM | +38.66% |
Annual EBITDA change of Reviva Pharmaceuticals (RVPH)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$3.19M | -83.91% |
| 2025 | -$20M | -33.63% |
| 2024 | -$30M | -23.79% |
| 2023 | -$39M | +38.85% |
| 2022 | -$28M | +179.60% |
| 2021 | -$10M | +315.64% |
| 2020 | -$2.43M | +539.47% |
| 2019 | -$380K | -240.74% |
| 2018 | $270K | N/A |
Comparison Reviva Pharmaceuticals (RVPH) five years EBITDA CAGR with competitors
Reviva Pharmaceuticals (RVPH) five years EBITDA CAGR is 48.17%.